Status:
RECRUITING
Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases
Lead Sponsor:
West China Hospital
Conditions:
Carcinoma
Colorectal Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The aim of this study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of R0 excision Colorectal Cancer Liver Metastases.
Eligibility Criteria
Inclusion
- Pathologically confirmed diagnosis of colorectal cancer； Karnofsky performance status 0-1; Patients with tumors identified by pathologic immunohistochemistry as pMMR or by genetic testing as MSS/MSI-L; Imaging diagnosis of stage IV, resection of both primary and metastatic tumors and had NED status after surgery; With a high risk of recurrence, such as liver metastasis CRS score \>3 or successful conversion therapy; Multiple peritoneal metastases after CC0; Function of the main organs is normal; Edition Patient's written informed consent
Exclusion
- Tumor emergencies; Abnormal coagulation function; Contagious diseases, such as HIV, HBV, HCV infection; Mental disorders; Concomitant tumors; Immunological co-morbidities
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06545630
Start Date
November 1 2023
End Date
May 1 2026
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorectal Cancer Center, West China Hospital
Chengdu, Chengdu/Sichuan, China, 610000